期刊
MOVEMENT DISORDERS CLINICAL PRACTICE
卷 4, 期 4, 页码 582-585出版社
WILEY
DOI: 10.1002/mdc3.12483
关键词
deutetrabenazine; Huntington's disease; indirect comparison; meta-analysis; tetrabenazine
资金
- TEVA
- CHDI Foundation
- GlaxoSmithKline
- Grunenthal
- Fundacao MSD (Portugal)
- MSD
- Allergan
- Ipsen
- Novartis
- Medtronic
- Medical Research Council
- GlaxoSmithKline Foundation
- UCL Consultants Ltd., a wholly owned subsidiary of UCL
- MRC [MR/M008592/1] Funding Source: UKRI
- Medical Research Council [MR/M008592/1] Funding Source: researchfish
BackgroundTetrabenazine is the only US Food and Drug Administration-approved drug for Huntington's disease, and deutetrabenazine was recently tested against placebo. A switching-trial from tetrabenazine to deutetrabenazine is underway, but no head-to-head, blinded, randomized controlled trial is planned. Using meta-analytical methodology, the authors compared these molecules. MethodsRCTs comparing tetrabenazine or deutetrabenazine with placebo in Huntington's disease were searched. The authors assessed the Cochrane risk-of-bias tool, calculated indirect treatment comparisons, and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. ResultsThe evidence network for this report comprised 1 tetrabenazine trial and 1 deutetrabenazine trial, both against placebo. Risk of bias was moderate in both. Participants in the tetrabenazine and deutetrabenazine trials did not differ significantly on motor scores or adverse events. Depression and somnolence scales significantly favored deutetrabenazine. ConclusionThere is low-quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety. It is important to note that these results are likely to remain the only head-to-head comparison between these 2 compounds in Huntington's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据